UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________
Form 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): November 14, 2014
|
BioCorRx Inc. |
|
(Exact name of registrant as specified in its charter) |
333-153381
(Commission File Number)
|
Nevada |
26-0685980 |
|
|
(State or other jurisdiction |
(I.R.S. Employer |
|
|
of Incorporation) |
Identification No.) |
601 N. Parkcenter Drive, Suite 103
Santa Ana, California 92705
(Address of principal executive offices)
(714) 462-4880
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Departure of Certain Officers
On November 14, 2014, Kent Emry resigned as the Chief Executive Officer of BioCorRx, Inc., a Nevada corporation (the “Company”), effective immediately. There are no disagreements between Mr. Emry and the Company on any matter relating to the Company’s SEC filings, accounting, operations, policies, or practices.
Item 9.01 Exhibits
The following exhibit is furnished as part of this Form 8-K:
Exhibit 99.1 Resignation Letter of Kent Emry, dated November 14, 2014.
|
2
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BIOCORRX INC. | |||
| Date: November 14, 2014 | By | /s/ Lourdes Felix | |
| Lourdes Felix | |||
| Chief Financial Officer and Director | |||
3